Johnson & Johnson (JNJ) July 149 straddle into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Johnson & Johnson (JNJ) gains as Q2 earnings, revenue beat estimates
July 17, 2024 6:39 AM EDTJohnson & Johnson (NYSE: JNJ) reported a robust second quarter, with both earnings and revenue surpassing Wall Street estimates.
The healthcare giant posted adjusted earnings per share (EPS) of $2.82, exceeding analyst predictions by $0.10, and a revenue of $22.45 billion, also topping the consensus estimate of $22.34 billion.
This performance represents a 4.3% increase in reported sales growth, with an operational growth of 6.6%.
The company's stock responded positively to the news, with shares rising 2.1% as investors reacted favorably... More
